dc.contributor.author | Burska, Agata | |
dc.contributor.author | Rodríguez-Carrio, Javier | |
dc.contributor.author | Biesen, Robert | |
dc.contributor.author | Dik, Willem A. | |
dc.contributor.author | Eloranta, Maija-Leena | |
dc.contributor.author | Cavalli, Giulio | |
dc.contributor.author | Visser, Marianne | |
dc.contributor.author | Boumpas, Dimitrios T. | |
dc.contributor.author | Bertsias, George | |
dc.contributor.author | Wahren Herlenius, Marie Elisabeth | |
dc.contributor.author | Rehwinkel, Jan | |
dc.contributor.author | Frémond, Marie-Louise | |
dc.contributor.author | Crow, Mary K. | |
dc.contributor.author | Ronnblom, Lars | |
dc.contributor.author | Conaghan, P.G. | |
dc.contributor.author | Versnel, Marjan | |
dc.contributor.author | Vital, Ed | |
dc.date.accessioned | 2023-10-05T13:02:07Z | |
dc.date.available | 2023-10-05T13:02:07Z | |
dc.date.created | 2023-06-16T10:40:12Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 2056-5933 | |
dc.identifier.uri | https://hdl.handle.net/11250/3094532 | |
dc.description.abstract | Objectives: To systematically review the literature for assay methods that aim to evaluate type I interferon (IFN-I) pathway activation and to harmonise-related terminology.
Methods: Three databases were searched for reports of IFN-I and rheumatic musculoskeletal diseases. Information about the performance metrics of assays measuring IFN-I and measures of truth were extracted and summarised. A EULAR task force panel assessed feasibility and developed consensus terminology.
Results: Of 10 037 abstracts, 276 fulfilled eligibility criteria for data extraction. Some reported more than one technique to measure IFN-I pathway activation. Hence, 276 papers generated data on 412 methods. IFN-I pathway activation was measured using: qPCR (n=121), immunoassays (n=101), microarray (n=69), reporter cell assay (n=38), DNA methylation (n=14), flow cytometry (n=14), cytopathic effect assay (n=11), RNA sequencing (n=9), plaque reduction assay (n=8), Nanostring (n=5), bisulphite sequencing (n=3). Principles of each assay are summarised for content validity. Concurrent validity (correlation with other IFN assays) was presented for n=150/412 assays. Reliability data were variable and provided for 13 assays. Gene expression and immunoassays were considered most feasible. Consensus terminology to define different aspects of IFN-I research and practice was produced.
Conclusions: Diverse methods have been reported as IFN-I assays and these differ in what elements or aspects of IFN-I pathway activation they measure and how. No ‘gold standard’ represents the entirety of the IFN pathway, some may not be specific for IFN-I. Data on reliability or comparing assays were limited, and feasibility is a challenge for many assays. Consensus terminology should improve consistency of reporting. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | BMJ | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2023 the authors | en_US |
dc.source.articlenumber | e002876 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1136/rmdopen-2022-002876 | |
dc.identifier.cristin | 2155204 | |
dc.source.journal | RMD Open | en_US |
dc.identifier.citation | RMD Open. 2023, 9 (1), e002876. | en_US |
dc.source.volume | 9 | en_US |
dc.source.issue | 1 | en_US |